Abbott and Eisai to launch Humira, rheumatoid arthritis therapy.

Published: 2007-03-20 06:57:00

Updated: 2007-03-20 06:57:00

Abbott Korea and Eisai Korea jointly launched a new type of rheumatoid arthritis drug called "Humira", having mode of selectively suppressing the TNF-alfa that linked with the occurrence and progress of the rheumatoid arthritis.

Unlike conventional RA therapy it is an antibody made by 100% of...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK